bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi
Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn